Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice

Nonalcoholic fatty liver disease (NAFLD), which is the most common liver disease, is associated with type 2 diabetes mellitus and metabolic syndrome. Although there is no consensus on the treatment of NAFLD, growing evidence suggests that tight glycemic control would contribute to the improvement of...

Full description

Bibliographic Details
Main Authors: Panshuang Qiao, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang, Hong Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
sodium-glucose cotransporter-2 inhibitor
nonalcoholic fatty liver disease
de novo lipogenesis
inflammation
fibrosis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.934136/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.934136/full

Similar Items